This section introduces Fumihisa Kojima’s profile and current activities. As Representative Director of Biozipcode Inc., he advances commercialization, fundraising, intellectual property utilization, and collaboration with domestic and international partners to bring research outcomes in the medical and biotech fields to society. Drawing also on knowledge of AI, computational science, and Web3, he plays a role in connecting research with social implementation.

This project combines the medical and healthcare fields with Web3, centered on GDT and Auring Ltd. It explores how diabetes research, 5-ALA, medical tourism, biomarker testing, online consultations, and related services may be connected with token-based and digital payment mechanisms. At the same time, because healthcare, investment, tokens, and overseas entities overlap in this area, the project is organized with an emphasis on legal, regulatory, and KYC/AML reviews.

Through joint research support with universities, Fumihisa Kojima has supported medical and biotech research from a technical perspective through analytical software, research systems, and large-scale computing environments. He continues to use AI, computational science, and data analysis to help connect research outcomes to commercialization in areas such as diabetes research, cell-targeting technologies, drug discovery support, and medical data analysis.

This is an overseas expansion project related to healthcare, investment, and business partnerships, with a view toward Palau, the UAE, the United States, and other regions. While building relationships with local medical institutions, government-related stakeholders, investors, and business partners, it explores possibilities for diabetes research, 5-ALA-related businesses, medical tourism, and Web3 projects. Because regulations and healthcare systems differ by country, the project is being developed on the premise of collaboration with local specialists.

This is a concept for advancing diabetes research and 5-ALA-related businesses not only in Japan, but also in collaboration with overseas medical institutions and partners. Rather than simply taking research outcomes overseas as they are, it seeks feasible implementation models while reviewing each country’s healthcare system, clinical research framework, pharmaceutical regulations, patient protection rules, and medical advertising requirements. Its purpose is to build a foundation for future clinical research, medical tourism, and collaboration with specialist physicians.